Zinc Oxide Nanoparticle-Poly I:C RNA Complexes: Implication as Therapeutics against Experimental Melanoma
There is current interest in harnessing the combined anticancer and immunological effect of nanoparticles (NPs) and RNA. Here, we evaluate the bioactivity of poly I:C (pIC) RNA, bound to anticancer zinc oxide NP (ZnO-NP) against melanoma. Direct RNA association to unfunctionalized ZnO-NP is shown by observing change in size, zeta potential, and absorption/fluorescence spectra upon complexation. RNA corona was visualized by transmission electron microscopy (TEM) for the first time. Binding constant (Kb = 1.6-2.8 g-1 L) was determined by modified Stern-Volmer, absorption, and biological surface activity index analysis. The pIC-ZnO-NP complex increased cell death for both human (A375) and mouse (B16F10) cell lines and suppressed tumor cell growth in BALB/C-B16F10 mouse melanoma model. Ex vivo tumor analysis indicated significant molecular activity such as changes in the level of phosphoproteins JNK, Akt, and inflammation markers IL-6 and IFN-γ. High throughput proteomics analysis revealed zinc oxide and poly I:C-specific and combinational patterns that suggested possible utility as an anticancer and immunotherapeutic strategy against melanoma.
antimelanoma, binding parameters, immunology, poly I:C RNA (pIC), zinc oxide nanoparticles (ZnO-NPs)
Ramani, Meghana, Miranda C. Mudge, R. Tyler Morris, Yuntao Zhang, Stanislaw A. Warcholek, Miranda N. Hurst, Jim E. Riviere, and Robert K. DeLong. "Zinc oxide nanoparticle–poly I: C RNA complexes: implication as therapeutics against experimental melanoma." Molecular Pharmaceutics 14, no. 3 (2017): 614-625.